CervoMed rises on patent news, pares gains after $10M equity sale
CervoMed shares soared to $7.75 intraday after announcing a U.S. patent allowance for neflamapimod in “pure” dementia with Lewy bodies patients, with protection expected into 2042, but gave back most gains after a $10 million share sale at $4 each; stock last up 8.7% at $4.14 on volume over 105 million shares.